Bivalirudin Side Effects: Safety Signals and Warnings
Bivalirudin safety concerns are compound-specific. The main listed side effects are Bleeding, Back pain, and Nausea. The main warning signals are Renal dose adjustment required - predominantly cleared renally, Increased stent thrombosis risk if infusion stopped abruptly, and No specific reversal agent available.
Direct Answer
Bivalirudin (Angiomax) is FDA-approved as an anticoagulant for PCI with Phase 3 data from the HORIZONS-AMI and ACUITY trials showing comparable efficacy to heparin plus GP IIb/IIIa inhibitors with significantly reduced bleeding risk. Its direct thrombin inhibition with predictable pharmacokinetics makes it a preferred anticoagulant in specific interventional cardiology settings.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Healing & Recovery
- Best for
- PCI anticoagulation, direct thrombin inhibitor pharmacology, reduced-bleeding anticoagulation research
Reported Side Effects
- Bleeding
- Back pain
- Nausea
- Hypotension
- Headache
Warnings
- Renal dose adjustment required - predominantly cleared renally
- Increased stent thrombosis risk if infusion stopped abruptly
- No specific reversal agent available
- Use caution with concomitant antiplatelet agents
Known or Plausible Interactions
- Heparin (should be discontinued before starting bivalirudin)
- GP IIb/IIIa inhibitors (additive bleeding risk)
- Thrombolytics (significantly increased bleeding)
- Warfarin (overlap period management required)
Regulatory Context
FDA-approved for use as an anticoagulant in patients undergoing PCI and for patients with or at risk of HIT undergoing PCI. Available by prescription for hospital use. Marketed as Angiomax by The Medicines Company. Generic versions available.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | PCI Anticoagulation (Level A), Reduced Major Bleeding (Level A), and Acute Stent Thrombosis (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Bivalirudin Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/bivalirudin-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.